These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16984333)

  • 21. [Efficacy of vaccination against hepatitis B in adult with HIV infection].
    Kalinowska-Nowak A; Bociaga-Jasik M; Garlicki A; Mach T
    Przegl Epidemiol; 2007; 61(2):339-47. PubMed ID: 17956052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV viral dynamic models with dropouts and missing covariates.
    Wu L
    Stat Med; 2007 Jul; 26(17):3342-57. PubMed ID: 17221835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statistical issues in the design of HIV vaccine trials.
    Schaper C; Fleming TR; Self SG; Rida WN
    Annu Rev Public Health; 1995; 16():1-22. PubMed ID: 7639865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of an AIDS vaccine in developing countries: a new model and initial results.
    Stover J; Bollinger L; Hecht R; Williams C; Roca E
    Health Aff (Millwood); 2007; 26(4):1147-58. PubMed ID: 17630459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mark-specific hazard ratio model with multivariate continuous marks: an application to vaccine efficacy.
    Juraska M; Gilbert PB
    Biometrics; 2013 Jun; 69(2):328-37. PubMed ID: 23421613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent trends in clinical trials of vaccines to prevent HIV/AIDS.
    Fast PE
    Curr Opin HIV AIDS; 2006 Jul; 1(4):267-71. PubMed ID: 19372820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virology. Moving forward in HIV vaccine development.
    Letvin NL
    Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
    [No Abstract]   [Full Text] [Related]  

  • 29. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A mouse model based on replication-competent Tiantan vaccinia expressing luciferase/HIV-1 Gag fusion protein for the evaluation of protective efficacy of HIV vaccine.
    Huang Y; Qiu C; Liu LX; Feng YM; Zhu T; Xu JQ
    Chin Med J (Engl); 2009 Jul; 122(14):1655-9. PubMed ID: 19719967
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incorporating founder virus information in vaccine field trials.
    Follmann D; Huang CY
    Biometrics; 2015 Jun; 71(2):386-96. PubMed ID: 25773491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 vaccine clinical trials: the Brazilian experience.
    Ersching J; Pinto AR
    Rev Med Virol; 2009 Sep; 19(5):301-11. PubMed ID: 19650156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with incarceration and incident human immunodeficiency virus (HIV) infection among injection drug users participating in an HIV vaccine trial in Bangkok, Thailand, 1999-2003.
    Suntharasamai P; Martin M; Vanichseni S; van Griensven F; Mock PA; Pitisuttithum P; Tappero JW; Sangkum U; Kitayaporn D; Gurwith M; Choopanya K;
    Addiction; 2009 Feb; 104(2):235-42. PubMed ID: 19149819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Murine models for HIV vaccination and challenge.
    Boberg A; Bråve A; Johansson S; Wahren B; Hinkula J; Rollman E
    Expert Rev Vaccines; 2008 Feb; 7(1):117-30. PubMed ID: 18251698
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges and regulatory experiences with non-inferiority trial design without placebo arm.
    Hung HM; Wang SJ; O'Neill R
    Biom J; 2009 Apr; 51(2):324-34. PubMed ID: 19358213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein.
    Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E
    AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical methods for the analysis of clinical trials data containing many zeros: An application in vaccine development.
    Callegaro A; Kassapian M; Zahaf T; Tibaldi F
    Stat Methods Med Res; 2016 Dec; 25(6):2811-2826. PubMed ID: 24845724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.